R&D JPM: The calm before the storm for radiotherapeutics Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.
Oncology ESMO25: Perspective on ‘inside-out oncology’ and targeted al... Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.